Klotho Neurosciences, Inc. (Nasdaq: KLTO) (“Klotho” or “The company”), a biotechnology company that develops Klotho-based therapeutics for neurodegenerative diseases, announces that CEO and Chairman Dr. Joseph Sinkule will take part in the opening conference and the scientific seminar of Klotho. The event, the first conference on the future of Klotho-based therapies and diagnostics, takes place in the UC-IRVINE BEAL Applied Innovation Center in Irvine, California, on September 15 and 16, 2025.
The two most important scientific advisors and inventors of the company, Dr. Miguel Chillon and Dr. Assumpcio Bosch will present your research results to research the Klotho-Genter therapy for the treatment of ALS, Alzheimer’s and in the area of durability.
Dr. Sinkule will be available for discussions with investors and potential partners during the conference. Interested parties can ir@klothoneuro.com turn around.
Information on Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (Nasdaq: KLTO) is a biogenetics company that focuses on the development of innovative, disease-modifying cell and gene therapies, in which a protein (S-KL) derived from a patented form of “anti-aging” gene (S-KL) and its novel administration systems are used for the treatment of neurodegenerative and Age -related diseases such as as a, Alzheimer’s and Parkinson’s better. The company’s current portfolio consists of its company-owned cell and gene therapy programs that DNA and RNA use as therapeutic agents, as well as genomic-based diagnostic tests. Klotho is guided by a team of individuals and consultants who have great experience in biopharmaceutical product development and marketing.
Future -oriented statements
This press release contains future -oriented statements. These statements are made as part of the “Safe Harbor” provisions of the US private securities litigation Reform Act from 1995. These future -oriented statements are generally in the terms “belief”, “project”, “expect”, “anticipate”, “appreciate”, “intend”, “strategy”, “future”, “opportunity”, “plan”, “should”, “would”, “would”, “continue”, “will probably result” and similar expressions. Without restricting the generality of the above, the future -oriented statements in this press release contain descriptions of the company’s future commercial activities. Future -oriented statements are predictions, projections and other statements about future events based on current expectations and assumptions and are therefore subject to risks and uncertainties. Many factors could lead to the fact that the actual future events differ significantly from the future -oriented statements in this press release, such as the inability of the company to implement its business plans, to recognize and implement additional opportunities or to fulfill or exceed its financial forecasts, as well as changes in the regulatory environment or in the competitive environment in which the company is active. You should carefully consider the above factors and the other risks and the other risks and imponderables described in the documents that the company submitted or submitted from time to time at the US Securities and Exchange Commission (“SEC”), since these could lead to the fact that the actual events and results deviate significantly from those that are included in the future -oriented statements. All information contained here corresponds to the status at the time of the publication of this press release, and the company is not obliged to update future -oriented statements, unless this is required by law.
Website: www.klothoneuro.com